View Item 

Show simple item record

Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs

dc.contributor.authorHawkey, C. J.en_US
dc.contributor.authorJones, R. H.en_US
dc.contributor.authorYeomans, N. D.en_US
dc.contributor.authorScheiman, James M.en_US
dc.contributor.authorTalley, Nicholas J.en_US
dc.contributor.authorGoldstein, J. L.en_US
dc.contributor.authorAhlbom, H.en_US
dc.contributor.authorNæ;sdal, J.en_US
dc.date.accessioned2010-06-01T20:34:01Z
dc.date.available2010-06-01T20:34:01Z
dc.date.issued2007-04en_US
dc.identifier.citationHAWKEY, C. J.; JONES, R. H.; YEOMANS, N. D.; SCHEIMAN, J. M.; TALLEY, N. J.; GOLDSTEIN, J. L.; AHLBOM, H.; NÆ;SDAL, J. (2007). "Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs." Alimentary Pharmacology & Therapeutics 25(7): 813-821. <http://hdl.handle.net/2027.42/73675>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73675
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17373920&dopt=citationen_US
dc.format.extent581515 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2007 The Authors Journal compilation 2007 Blackwell Publishing Ltden_US
dc.titleEfficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum§ Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationother* Institute of Clinical Research Trials Unit, University Hospital, Nottinghamen_US
dc.contributor.affiliationother† GKT Department of General Practice and Primary Care, King's College London, London, UKen_US
dc.contributor.affiliationother† University of Western Sydney Medical School, Sydney, Australiaen_US
dc.contributor.affiliationother¶ Mayo Clinic College of Medicine, Rochester, MNen_US
dc.contributor.affiliationother** Department of Medicine, University of Illinois at Chicago, Chicago, IL, USAen_US
dc.contributor.affiliationother†† AstraZeneca R&D, MÖlndal, Swedenen_US
dc.identifier.pmid17373920en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73675/1/j.1365-2036.2006.03210.x.pdf
dc.identifier.doi10.1111/j.1365-2036.2006.03210.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceMcCarthy D. Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology. Am J Med 1998; 105: 3S – 9S.en_US
dc.identifier.citedreferenceCullen DJ, Seager JM, Holmes S, et al. Pharmacoepidemiology of non-steroidal anti-inflammatory drug use in Nottingham general practices. Aliment Pharmacol Ther 2000; 14: 177 – 85.en_US
dc.identifier.citedreferenceVoutilainen M, Sipponen P, Mecklin JP, Juhola M, Farkkila M. Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion 2000; 61: 6 – 13.en_US
dc.identifier.citedreferenceWolfe F, Hawley DJ. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol 2000; 27: 1668 – 73.en_US
dc.identifier.citedreferenceKotzan J, Wade W, Yu HH. Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population. Pharm Res 2001; 18: 1367 – 72.en_US
dc.identifier.citedreferenceLaine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum 2002; 32 ( 3 Suppl. 1 ): 25 – 32.en_US
dc.identifier.citedreferenceLangman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929 – 33.en_US
dc.identifier.citedreferenceSilverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 2000; 282: 1247 – 55.en_US
dc.identifier.citedreferenceLisse JE, Perlman M, Johannson G, et al. Gastrointestinal tolerability and effectiveness of rofecoxib vs. naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Inter Med 2003; 139: 539 – 46.en_US
dc.identifier.citedreferenceVeldhuyzen van Zanten SJO, Bradette M, Chiba N, et al. Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. Can J Gastroenterol 2005; 19: 285 – 303.en_US
dc.identifier.citedreferenceSingh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective-1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 1998; 25 ( Suppl. 51 ): 8 – 16.en_US
dc.identifier.citedreferenceElliot SL, Ferris RJ, Giraud AS, et al. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol 1996; 23: 432 – 4.en_US
dc.identifier.citedreferenceMcCarthy DM. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs. Best Pract Clin Gastroenterol 2001; 15: 755 – 73.en_US
dc.identifier.citedreferenceEkstrom P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996; 31: 753 – 8.en_US
dc.identifier.citedreferenceYeomans N, Wilson I, Langstrom G, et al. Quality of life in chronic NSAID users: a comparison of the effect of omeprazole and misoprostol. Scand J Rheumatol 2001; 30: 328 – 34.en_US
dc.identifier.citedreferenceHawkey C, Talley NJ, Yeomans ND, et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005; 100: 1028 – 36.en_US
dc.identifier.citedreferenceScheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101: 701 – 10.en_US
dc.identifier.citedreferenceGoldstein JL, Johansen JF, Suchower LJ, Brown KA. Healing of gastric ulcers with esomeprazole vs. ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am J Gastroenterol 2005; 100: 2650 – 7.en_US
dc.identifier.citedreferenceJunghard O, Lauritsen K, Talley NJ, et al. Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non-ulcer dyspepsia. Eur J Surg Suppl 1998; 583: 106 – 11.en_US
dc.identifier.citedreferenceJunghard O, Wiklund I. Validation of a 4-graded scale for severity of heartburn in symptomatic GERD patients [abstract]. Gut 2004; 53 ( Suppl. VI ): A103.en_US
dc.identifier.citedreferenceHirschowitz BI. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. Gastroenterologist 1994; 2: 207 – 23.en_US
dc.identifier.citedreferenceTenenbaum J. The epidemiology of nonsteroidal anti-inflammatory drugs. Can J Gastroenterol 1999; 13: 119 – 22.en_US
dc.identifier.citedreferenceJohnson DA, Fennerty MB. Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease. Gastroenterology 2004; 126: 660 – 4.en_US
dc.identifier.citedreferenceAllen A, Flemstrom G, Garner A, Kivilaakso E. Gastroduodenal mucosal protection. Physiol Rev 1993; 73: 823 – 57.en_US
dc.identifier.citedreferenceRich M, Scheiman JM. Nonsteroidal anti-inflammatory drug gastropathy at the new millennium: mechanisms and prevention. Semin Arthritis Rheum 2000; 30: 167 – 79.en_US
dc.identifier.citedreferenceLevine RA, Schwartzel EH. Effect of indomethacin on basal and histamine-stimulated human gastric acid secretion. Gut 1984; 25: 718 – 22.en_US
dc.identifier.citedreferenceSavarino V, Mela GS, Zentilin P, et al. Effect of one-month treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) on gastric pH of rheumatoid arthritis patients. Dig Dis Sci 1998; 43: 459 – 63.en_US
dc.identifier.citedreferenceKulkarni SG, Parikh SS, Shankhpal PD, et al. Gastric emptying of solids in long-term NSAID users: correlation with endoscopic findings and Helicobacter pylori status. Am J Gastroenterol 1999; 94: 382 – 6.en_US
dc.identifier.citedreferenceBouras EP, Burton DD, Camilleri M, Stephens DA, Thomforde GM. Effect of cyclooxygenase inhibitors on gastric emptying and small intestinal transit in humans. Neurogastroenterol Motil 2004; 16: 729 – 35.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2036.2006.03210.x.pdf
Size:
567.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.